Mishcon advises Quotient Bioresearch on sale

Posted on 09 February 2016

Mishcon de Reya LLP advises the sellers of Quotient Bioresearch Group Limited on its sale to Pharmaron

Mishcon de Reya LLP has advised the sellers of Quotient Bioresearch Group Limited on its sale to Pharmaron.

Quotient Bioresearch provides radiochemistry, drug metabolism and e-fate solutions to pharmaceutical, biotechnology, agrochemical and chemical sponsors worldwide.

Pharmaron, headquartered in China, has premier expertise in drug R&D services including discovery and pre-clinical safety and early phase DMPK. By acquiring Quotient's radiochemistry capabilities, Pharmaron aims to enhance its service portfolio and create a global leading chemistry platform with full spectrum of services and increase its presence in global markets, particularly in Asia, Europe and the U.S.

The advisory team at Mishcon de Reya was led by Corporate Partner Richard Tyler, assisted by Corporate Associate James Paterson, Corporate Trainee Solicitor Jennifer Anderson, Employment Managing Associate Will Winch, Tax Associate Sarah Howes, Real Estate Partner Simon Hart and Real Estate Associate Kim Chalkin.

Richard Tyler commented: "This transaction marks the disposal of the last part of the Quotient Group which the firm has been acting for since 2008 on a number of major acquisitions and fundraisings, and since 2010 on a disposal program which included the sale of Quotient Clinical Limited to Bridgepoint Development Capital and HFL Sport Science Limited to LGC. We are very pleased to have been so closely involved throughout the Quotient journey."

Roger Burdett, Quotient Chairman commented: "The partnership with Mishcon de Reya over the last eight years allowed Mishcon to obtain a unique insight to the Quotient Group and led to a closer collaborative working relationship during the evolution of the Group.”

William Blair International acted as financial advisers to the sellers.